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Synthesis and evaluation of 3-amino/guanidine
substituted phenyl oxazoles as a novel class of LSD1
inhibitors with anti-proliferative properties†
Balakrishna Dulla,a,b Krishna Tulasi Kirla,c Vandana Rathore,c Girdhar Singh Deora,b
Sridhar Kavela,d Subbareddy Maddika,d Kiranam Chatti,c Oliver Reiser,*a
Javed Iqbal*b and Manojit Pal*b
A series of functionalized phenyl oxazole derivatives was
designed, synthesized and screened in vitro for their activities
against LSD1 and for eﬀects on viability of cervical and breast
cancer cells, and in vivo for eﬀects using zebraﬁsh embryos. These
compounds are likely to act via multiple epigenetic mechanisms
speciﬁc to cancer cells including LSD1 inhibition.
Histones are proteins that bind to DNA and facilitate eﬃcient
‘packing’ of DNA in eukaryotic cells.1 They are highly basic in
nature due to the presence of positively charged amino acid
side chains causing the DNA to fold around them into
compact structures (nucleosomes). The ability of histones to
regulate gene expression is controlled by post-translational
modifications on the N-terminal (and likely C-terminal) “tails”
of the core histones which project out of the nucleosome.
Modifications including phosphorylation, acetylation, methyl-
ation, ubiquitination, sumoylation and biotinylation have
been identified on the histone tails.2 The cellular roles of
histone lysine acetylation/deacetylation are the best character-
ized of the histone modifications – acetylation normally acti-
vates transcription whereas deacetylation deactivates this
process.3 Although there are clear links to disease,4–8 the role
of histone methylation is much less understood and appears
to be context dependent.
LSD1 (lysine specific demethylase 1) was the first histone
demethylase identified. Its discovery significantly advanced
the understanding of epigenetic regulation of gene expression,
changing the paradigm that methylation is a non-reversible
feature of histones.9 Histone methylation/demethylation has
since been found to be an important epigenetic modification
linked to activation as well as repression of transcription. Two
types of histone demethylases have been discovered. The
flavin-dependent demethylase LSD1 acts on lysine 4 and lysine
9 of histone H3 (H3K4 and H3K9). LSD1 selectively catalyzes
the oxidation of the methyl group of mono- and dimethylated
lysines resulting in an imine intermediate and generation of
hydrogen peroxide. The imine product is non-enzymatically
hydrolysed to generate a carbinolamine resulting in demethy-
lated lysine and formaldehyde release.10 The other major
class, i.e. Jumonji domain-containing histone demethylases,
are Fe(II) and 2-oxoglutarate dependent oxygenases that act on
mono-, di- and trimethylated Lys and methylated Arg residues
depending on the particular enzymes.11 Histone demethylase
activity is associated with several pathological states. Increased
LSD1 expression in prostate tumors correlates significantly
with relapse during therapy.6,7 Suppressed LSD1 expression is
associated with vascular smooth muscle cell inflammatory
damage in a mouse model of diabetes.8 Demethylation of p53
(tumor suppressor) by LSD1 prevents p53 interaction with its
co-activator 53BP1.5 Activation of the telomerase reverse tran-
scriptase (hTERT) gene is known to be dependent on LSD1
levels and recruitment to the hTERT promoter.4
Studies on LSD1 have identified a few classes of molecules
that exhibit inhibitory activity. Several monoamine oxidase
inhibitors (MAOIs), more commonly used as antidepressants,
inhibit LSD1, indicating one possible direction for small
molecule design.12 Biguanide and bisguanidine polyamine
analogs are another class of molecules that was identified for
this process. These molecules have been used in cultured
colon cancer cells to demonstrate LSD1 inhibition and resul-
tant activation of silenced genes.13 Peptides containing meth-
ionine as the key structural element also showed LSD1
inhibition. However, none of these molecules are likely to be
selective for LSD1 or are drugable. Small molecules which can
selectively modulate the activity of LSD1 should therefore hold
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great promise in two main areas – (1) in laboratory experi-
ments to understand the cellular and physiological eﬀects of
LSD1 inhibition and the interaction of histone
H3K4 methylation with other epigenetic modifications such as
histone acetylation, histone phosphorylation and DNA methy-
lation; (2) in animal studies aimed at defining the potential of
clinical therapy as LSD1 inhibitors for the treatment of chronic
conditions such as cancer, diabetes and obesity. Herein, we
report the synthesis and biological study of a novel class of
molecules as probes of LSD1 function, as possible epigenetic
modulators or as potential anti-cancer agents.
Using the available X-ray diﬀraction crystal structure of
LSD1 as a starting point,14 we designed a series of small mole-
cules as potential inhibitors taking the key pharmacophore
features identified for the MAO, the polyamine/guanidine and
methionine based peptide inhibitors, into account
(Fig. 1)12,13,15–20 being linked through an oxazole moiety. The
oxazole linker was chosen as a cyclic bioisostere of an amino
acid. The reason for introducing the guanidine or amino
group meta into the oxazole moiety on the benzene ring was to
avoid long conjugation and thereby potential activation of the
oxazole moiety towards metabolism. The Schrodinger mole-
cular modelling suite was used to visualize the three-dimensional
structure of LSD1 and predict the docking sites, inhibitory
interactions and the theoretical eﬀectiveness of small
molecules.
The synthesis of target compounds and their derivatives
was eﬃciently performed using the reaction sequence as
shown in Scheme 1. 3-Nitrobenzamide derivatives 221,22 were
readily obtained by reacting appropriate 3-nitrobenzoic acids 1
with methionine methylester hydrochloride in the presence of
HBTU, followed by treatment with LiOH·H2O to give rise to the
corresponding carboxylic acids 3.23 Those were subsequently
converted into keto-amides 4 in the presence of acetic an-
hydride and pyridine via a Dakin–West type reaction.24 After
Fig. 1 Design of novel LSD1 inhibitors based on pharmacophore similarity
with reported inhibitors.
Scheme 1 Synthesis of 3-amino/guanidine substituted phenyl oxazoles.
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refluxing with POCl3, the keto-amides 4 cyclized spontaneously
to produce the 3-nitrophenyl oxazole derivatives 524 which on
reduction with SnCl2·2H2O aﬀorded 3-aminophenyl oxazole
derivatives 6.25 The installation of a bis-BOC protected 3-guani-
dine group was achieved by treating 6 with N1,N2-bis-(tert-
butoxycarbonyl)-S-methylisothiourea (7),26 to give the corres-
ponding 3-guanidine phenyloxazole derivatives 8. Finally, on
deprotection with trifluoroacetic acid, 3-guanidine phenyl
oxazole derivatives 9 were obtained.26 A number of N-substi-
tuted derivatives (10–14) were also prepared via N-acylation,
N-sulfonation or N-alkylation of 6b (Scheme 2). All synthesized
compounds were fully characterized by spectroscopic methods
(NMR, IR, MS and HRMS).
Having synthesized the desired target molecules 6 and 9
along with 10–14 we performed their pharmacological evalu-
ation in vitro determining the cell viability by a MTT assay.
Initially, these compounds were subjected to the cervical
cancer cell line HeLa and the breast cancer cell line
MDA-MB-231 with concentrations ranging from 0.5 nM to 3.7
nM (log concentrations) for 36 h. Among the compounds
tested 6a, 6b, 9a and 9c showed significant inhibitory eﬀects
on these cells (Table 1; for graphs see ESI†). From these data it
was evident that a guanidine moiety did not oﬀer any signifi-
cant advantages over an amino group (e.g. 9a and 9c vs. 6a and
6b) with respect to in vitro activities. Subsequent dose response
studies were performed to calculate the IC50 values that were
found to be in the range of 10–16 μM.
We focused next on evaluating zebrafish embryo toxicity
and apoptosis. Embryos of the zebrafish Danio rerio are excel-
lent animal models for studying the eﬀects of small molecules
on early development and on toxicity, thus allowing eﬀective
in vivo evaluations of potential drugs before embarking on
expensive studies on mice and humans.27 The histone
demethylase LSD1 is known to be encoded by the zebrafish
genome,28 and the protein sequence has 85% sequence iden-
tity with that of human LSD1 protein making the zebrafish
embryo an attractive in vivo model. Compounds 6b, 6c and 9b
showed general toxicity-related eﬀects in zebrafish embryos,
resulting in death after 24 h of exposure at 10 μM. In contrast,
compounds 6b, 9a and 9c showed increased apoptosis at
10 μM with no general toxicity-related eﬀects even after 72 h of
treatment (Table 1, Fig. 2). The data clearly suggest an
increased apoptosis as indicated by acridine orange fluore-
scence, especially in the area of the brain. This observation
is consistent with reported brain-related eﬀects of LSD1
inhibition.29
Our results indicate that compounds 6a, 6b, 9a and 9c
possess biological activity related to the mechanisms involved
in cell viability. The data from in vitro LSD1 inhibition are con-
sistent with compounds 6a, 6b and 9a possessing LSD1 inhi-
bitory properties, although the IC50 values are higher by an
order of 104. This suggests that the activity of the compounds
on the cells tested is mediated by additional eﬀects apart from
LSD1 inhibition. Possible eﬀects include those on epigenetic
modifications other than histone methylation, such as histone
acetylation and DNA methylation, leading to a significant sup-
pression of cell viability. Such non-specific epigenetic eﬀects
are plausible because the compounds were designed based on
structural features of the LSD1 protein and that of other
known inhibitors of LSD1. The data from studies with zebra-
fish embryos showed that compounds 6b, 9a and 9c resulted
in a significant increase in apoptosis, with no general toxicity-
related eﬀects. The treatment was done at a concentration of
10 μM, which was in the range of in vitro LSD1 inhibition IC50
values. The significant diﬀerence in activity shown by these
Scheme 2 Synthesis of analogues 10–14 of 6b.
Table 1 Summary of the pharmacological evaluation of compounds 6a, 6b, 9a and 9c
Pharmacological activity
HeLa cell viability (IC50) 1.29 nM 1.22 nM 1.48 nM 2.14 nM
MDA-MB-231 cell viability (IC50) 1.328 nM 1.202 nM 1.328 nM 1.035 nM
In vitro LSD1 inhibition (IC50) 16.1 μM 10.1 μM 9.5 μM >50 μM
Zebrafish embryo apoptosis Insignificant Yes (10 μM) Yes (10 μM) Yes (10 μM)
Zebrafish embryo toxicity None None Not done None
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compounds in cells and in zebrafish embryos suggests that the
cancer cells used may possess features (such as specific
mutations or epigenetic targets) that make them more sensi-
tive to the eﬀects of LSD1 inhibition, compared to the develop-
ing zebrafish embryos which represent a non-diseased, living
organism. This is plausible since cancer cells are known to
have several accumulated defects compared to normal cells.
Our data thus support the possibility that the compounds are
selective for cancer cells over normal cells. Overall, the results
of our detailed pharmacological analysis suggest that com-
pounds 6b and 9a possess biological activity consistent across
in vitro, cell culture and in vivo systems.
To understand the binding mode and stability of ligand
receptor complexes we performed molecular modeling studies
(Docking analysis and Molecular dynamics simulations) using
6a, 6b and 9a against LSD1 (Fig. 3, see also ESI†). Docking
studies predicted good interactions with the LSD1 enzyme.
The guanidine group of 9a interacted with Glu-308 and Arg-
310 via H-bonds whereas the phenyl ring participated in a
π-cation interaction with Arg-316. In the case of 6b, (i) the free
–NH2 formed a H-bond bond with Ser-760, (ii) the sulfur atom
formed a H-bond with Met-332 and Val-333 and (iii) the
phenyl ring participated in π–π stacking with Trp-751 and Tyr-
761 residues. In the case of 6a, (i) the free –NH2 and the
oxazole nitrogen were involved in H-bonding with Thr-624 and
Arg-316 respectively, and (ii) the oxazole ring participated in a
π–cation interaction with Arg-316.
Furthermore, the molecular dynamics (MD) simulations of
9a at the binding site of protein were also performed using the
Desmond package incorporated in Maestro. To evaluate the
stability of the MD trajectories and the diﬀerences in stability
of the MD simulations, the total energy of the ligand–protein
complex and RMSD values for the protein backbone atoms
relative to the initial minimized structure through the phase of
the simulation were calculated. There was no significant
change in the total energy of the system observed during the
entire simulation period. The RMSD values remained within
6.0 Å for the system after reaching equilibrium, which demon-
strated the conformational stabilities of the protein structures.
Throughout the MD simulations, the studied compound main-
tained its binding pose in the expected orientation.
In summary, we have designed, synthesized and performed
pharmacological analysis of 3-amino/guanidine substituted
phenyl oxazoles as a novel class of LSD1 inhibitors and likely
epigenetic modulators. These molecules were conveniently pre-
pared via a multistep sequence involving an amide bond for-
mation, construction of an oxazole ring and introduction of a
guanidine moiety as key steps. Among the compounds tested,
6a, 6b and 9a showed promising activities against LSD1
Fig. 2 Zebraﬁsh embryos treated with compounds 6b and 9c and stained with
acridine orange. Brightly stained spots highlighted with a circle represent apop-
totic cells with fragmented nuclei.
Fig. 3 Binding orientation and interactions of 9a at the LSD1 inhibitors
binding site.
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(IC50 ∼ 10–16 μM) and cancer cells (IC50 = 1.2–1.4 nM) in vitro.
Additionally, the compounds 6b and 9a were found to increase
apoptosis in zebrafish embryos in the brain area when evalu-
ated in a phenotype-based zebrafish assay. All these com-
pounds showed good binding interactions with the LSD1
enzyme in silico as indicated by docking studies. Overall, our
study provides the basis for future work which can be directed
at elucidating the details of mechanisms of action of the com-
pounds presented and the contribution of specific structural
features to their activity.
The authors thank the management of DRILS for support
and B. D. thanks the DAAD (Indigo) for providing a fellowship.
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